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Abstract
Accurate and sensitive measurement techniques are a key issue
in the quantification of the microvascular and endothelial
dysfunction in systemic sclerosis (SSc). Thermal hyperhemia
comprises two separate mechanisms: an initial peak that is axon
reflex mediated; and a sustained plateau phase that is nitric
oxide dependent. The main objective of our study was to test
whether thermal hyperhemia in patients with SSc differed from
that in patients with primary Raynaud's phenomenon (RP) and
healthy controls. In a first study, we enrolled 20 patients
suffering from SSc, 20 patients with primary RP and 20 healthy
volunteers. All subjects were in a fasting state. Post-occlusive
hyperhemia, 0.4 mg sublingual nitroglycerin challenge and
thermal hyperhemia were performed using laser Doppler
flowmetry on the distal pad of the third left finger. In a second
study, thermal hyperhemia was performed in 10 patients with
rheumatoid arthritis and 10 patients with primary RP. The
thermal hyperhemia was dramatically altered in terms of
amplitude and kinetics in patients with SSc. Whereas 19 healthy
volunteers and 18 patients with primary RP exhibited the classic
response, including an initial peak within the first 10 minutes
followed by a nadir and a second peak, this occurred only in four
of the SSc patients (p < 0.0001). The 10 minutes thermal peak
was 43.4 (23.2 to 63), 42.6 (31 to 80.7) and 27 (14.7 to 51.4)
mV/mm Hg in the healthy volunteers, primary RP and SSc
groups, respectively (p = 0.01), while the 44°C thermal peak
was 43.1 (21.3 to 62.1), 42.6 (31.6 to 74.3) and 25.4 (15 to
52.4) mV/mm Hg, respectively (p = 0.01). Thermal hyperhemia
was more sensitive and specific than post-occlusive hyperhemia
for differentiating SSc from primary RP. In patients with
rheumatoid arthritis, thermal hyperhemia was also altered in
terms of amplitude. Thermal hyperhemia is dramatically altered
in patients with secondary RP in comparison with subjects with
primary RP. Further studies are required to determine the
mechanisms of this altered response, and whether it may
provide additional information in a clinical setting.
Introduction
Vascular dysfunction is a key element of the systemic sclerosis
(SSc) disease process, and involves both the micro and mac-
rovasculature [1]. The microcirculation undergoes structural
and functional changes that are interdependent. This microan-
giopathy is characterized by capillary rarefaction, development
of megacapillaries and vascular obliteration [2], which are
associated with functional abnormalities mainly related to an
endothelial dysfunction. Endothelial cells seem to play a piv-
otal role in SSc pathogenesis via the impairment of endothe-
lium-dependent vasodilation and an increased
transendothelial migration of T lymphocytes [3,4]. Endothe-
lium-dependent vasodilation is impaired in patients with SSc
mainly through an impaired ability to release nitric oxide (NO),
and is an early event in the disease process [1,5]. Furthermore,
patients with SSc have fewer endothelial progenitor cells than
controls, and those present are often dysfunctional as well [6].
dcSSc = diffuse cutaneous systemic sclerosis; lcSSc = limited cutaneous systemic sclerosis; NO = nitric oxide; RA = rheumatoid arthritis; RP = 
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Accurate and sensitive measurement techniques are a key
issue in the quantification of this vascular dysfunction, espe-
cially endothelial dysfunction. Different techniques have been
used to quantify the microvascular dysfunction in SSc, such as
microinjection [7], video microscopy [8], iontophoresis [9] or
venous occlusion plethysmography [3], whereas endothelial
function of conductance arteries can be monitored using ultra-
sonography of the brachial artery [10]. An easier non-invasive
technique for monitoring cutaneous vascular function is the
response to a given physiological challenge using cutaneous
laser Doppler flowmetry. Using cold tests, the response of skin
cutaneous blood flow does not significantly differ between pri-
mary Raynaud's phenomenon (RP) and SSc [11-13]. The
response to brachial artery occlusion, however, gives more
interesting results. Indeed, several authors showed a dramatic
alteration of the amplitude and kinetics of post-occlusive
hyperhemia in patients with SSc in comparison with primary
RP or healthy controls [14,15], whereas an altered amplitude
but not altered kinetics was described by Rajagopolan et al.
[12]. Although the reproducibility of the method is debated,
post-occlusive hyperhemia has been proposed for use as a
tool to assess microvascular function during therapy in dis-
eases such as atherosclerosis [16,17]. This post-occlusive
hyperhemia is due both to metabolic and endothelium derived
factors. We found, however, using microdialysis and laser
Doppler flowmetry, that NO release is not directly involved in
such as response [18], which limits the interest of post-occlu-
sive hyperhemia as a test of endothelial function in SSc. In
contrast, local hyperhemia to local heating in a small area of
skin provides interesting information as thermal hyperhemia
comprises two separate mechanisms: an initial peak that is
axon reflex mediated; and a sustained plateau phase that is
NO dependent [19,20]. Thermal hyperhemia might, therefore,
be a better tool to assess both endothelial and microvascular
function than post-occlusive hyperemia, and as such was
recently investigated as a clinical tool to assess endothelial
function in diseases such as chronic renal failure [21].
The main objective of our study was to test whether thermal
hyperhemia in patients with SSc differed from that in patients
with primary RP and healthy controls. The secondary objec-
tives were: to compare the kinetics and amplitude of thermal
hyperhemia in patients with local or diffuse SSc; to assess any
relationship with the Rodnan skin score; and to determine the
sensitivity and specificity of thermal hyperhemia in comparison
to post occlusive hyperhemia in order to distinguish patients
with SSc from those with RP. Given the altered response to
local heating we observed in SSc, we also tested in a second
study whether this was specific or not, enrolling patients with
rheumatoid arthritis, another connective tissue disease that




The first study compared thermal hyperhemia in patients with
systemic sclerosis with that in patients with primary Raynaud's
phenomenon and healthy controls. We studied 60 consecu-
tive subjects at the Inserm Clinical Research Center (Greno-
ble University Hospital, Grenoble, France) from January 2004
to October 2004: 20 patients suffering from systemic sclero-
sis, 20 patients with primary Raynaud's phenomenon and 20
healthy volunteers. These subjects are involved in a larger
cohort study of the vascular phenotype of SSc. The criteria for
inclusion in the study in the SSc cohort were diagnosis of SSc
according to the criteria of the American College of Rheuma-
tology [22], and age above 18 years old. SSc was classified
as limited cutaneous (lcSSc) or diffuse cutaneous SSc
(dcSSc) according to the criteria of LeRoy et al. [23]. Exclu-
sion criteria were cigarette smoking, diabetes mellitus, hyper-
cholesterolemia, or any associated severe disease (cancer,
cardiac and pulmonary failure, myocardial infarction, angina
pectoris). Furthermore, patients receiving statins, nitrates or
non-steroidal anti-inflammatory drugs were excluded. All
patients were asked to discontinue any vasodilator therapy
given for Raynaud's phenomenon one week before inclusion
and until the end of the study. Patients unable to discontinue
vasodilator therapies during the study period were not
included.
The onset of the disease was defined as the first occurrence
of symptoms of SSc except for RP. Digital pitting scars,
esophageal dysfunction and RP were diagnosed clinically.
Skin thickness was quantified using the modified Rodnan skin
score [24]. The diagnosis of pulmonary fibrosis was sus-
pected on the basis of clinical data and systematic radio-
graphs, and confirmed in all cases by computed tomography
scans.
Primary RP was diagnosed according to the criteria of LeRoy
and Medsger [25], including a normal nailfold capillaroscopy,
the lack of antinuclear antibodies, no digital pitting scar and
the lack of clinical symptoms of connective tissue disease.
This was a descriptive monocentric controlled study. All sub-
jects gave informed written consent. The study was approved
by the institutional review board of Grenoble University Hospi-
tal, France, on January 2004. Eligibility criteria and clinical sta-
tus were assessed, and instructions for vasodilator therapy
withdrawal were given to each subject. Twenty patients suffer-
ing from SSc were recruited from the Vascular Medicine
Department. When a patient with SSc was enrolled, they were
matched (sex and age ± 5 years) with a patient with Raynaud's
phenomenon and a healthy volunteer. All patients with Ray-
naud's phenomenon and healthy volunteers were recruited
through local newspaper advertisements.Available online http://arthritis-research.com/content/7/5/R1103
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All subjects arrived at the Clinical Research Center in Greno-
ble University Hospital between 8 a.m. and 9 a.m. in a fasting
state, where the following measurements were performed
within one day in a quiet room with a stable ambient tempera-
ture. After clinical examination, subjects were placed in a
supine position with both forearms resting at heart level. Blood
pressure and heart rate were determined and electrocardiog-
raphy was performed, followed by laser Doppler measure-
ments on the left arm. Venous blood samples were taken at
fast for blood lipids and plasma glucose determination either
before or after the laser Doppler measurements. Thereafter,
subjects underwent echocardiography. Patients with SSc
underwent pulmonary function testing.
Second study
Given the altered response to local heating we observed in
SSc, we also tested in a pilot study whether this altered
response was specific to this connective tissue disease. We
studied 10 consecutive subjects with rheumatoid arthritis (RA)
in the Rheumatology Department (Grenoble University Hospi-
tal, Grenoble, France) and 10 sex and age-matched (± 5
years) patients with primary Raynaud's phenomenon in the
Inserm Clinical Research Center (Grenoble University Hospi-
tal, Grenoble, France), from April 2005 to May 2005. All sub-
jects gave informed written consent. The study was approved
by the institutional review board of Grenoble University Hospi-
tal, France, on April 2005. The criteria for inclusion in the study
in the RA group were diagnosis of RA according to the Amer-
ican College of Rheumatology [26], and age above 18 years
Table 1
Demographic, clinical and biological characteristics of patients enrolled in the first study
Healthy controls (n = 20) Primary RP (n = 20) SSc (n = 20)
Age (years) 47 (37–58) 46 (37–59) 50 (33–61)
Female 18 (90%) 18 (90%) 18 (90%)
Body mass index (kg/m2) 22 (20–29) 20 (18–23) 23 (20–26)
Raynaud's phenomenon 0 20 (100%) 20 (100%)
Median Raynaud's disease duration (years) 0 18 (6–43) 8 (3–22)
Raynaud's phenomenon: median number of fingers involved 0 8 (6–10) 10 (8–10)
Raynaud's phenomenon: thumb involved 0 7 (35%) 18 (90%)
Raynaud's phenomenon: feet involved 0 8 (40%) 16 (80%)
Median disease duration (years) NA NA 5 (0,5–16)
Digital pitting scars 0 0 8 (40%)
Sclerodactyly 0 0 20 (100%)
Median Rodnan modified skin score 0 0 6 (2–29)a
dcSSc/lcSSc 0/0 0/0 6/14
Pulmonary fibrosis 0 0 7 (35%)
Esophageal dysmotility 0 0 13 (65%)
Median creatinine clearance (ml/min) 81.7 (66–119) 74.9 (68–97) 87.9 (79–139)
Microalbuminuria (mg/l) 11 (11–17.6) 11 (11–20.8) 11 (11–17.7)
Median cardiac rate (beat/min) 62 (49–77) 69 (52–92) 65 (57–78)
Median systolic/diastolic blood pressure (mm Hg) 111 (99–133)/ 66 (54–78) 107 (91–122)/ 62 (52–79) 106 (89–141)/ 67 (54–85)
Median oxygen saturation (%) 99 (97–100) 100 (97–100) 100 (96–100)
Autoantibodies
Anti-centromere 0 0 8 (40%)
Anti-topoisomerase I 0 0 5 (25%)
Median plasma LDL cholesterol (g/l) 1.04 (0.7–1.4) 1.04 (0.6–1.4) 0.9 (0.6–1.2)
Median plasma triglycerides (g/l) 0.7 (0.3–1) 0.5 (0.4–0.9) 0.7 (0.3–0.9)
Median plasma glycemia (mmol/l) 4.7 (3.6–5.3) 4.6 (4–5.7) 4.6 (4.3–5.2)
Quantitative data are medians, with 10th and 90th percentiles in parentheses. Qualitative data are expressed as numbers. aThe median Rodnan 
modified skin score was 4 (2–11) for the limited cutaneous systemic sclerosis (lcSSc) and 25 (12–43) for the diffuse cutaneous systemic sclerosis 
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old. The criteria for inclusion in the study in the primary RP
group were the same as in the main study. All subjects under-
went thermal hyperhemia testing using the methodology
detailed below.
Laser Doppler measurements
Cutaneous blood flow was measured using a laser Doppler
flowmeter (PeriFlux System 5000, Perimed, Järfälla, Sweden).
A laser probe (PR457) was attached to the distal pad of the
third left finger and left in place during all the laser Doppler
measurements. Data from the laser Doppler flowmeter were
interfaced to a personal computer through a converter using
Perisoft® data acquisition software.
Laser Doppler blood flow was recorded in mV, which are
directly related to blood flow in the microcirculation of the sur-
face tissue. Red blood cell flux values were divided by mean
arterial pressure to yield a value of cutaneous vascular con-
ductance expressed as mV/mm Hg. The expression of data in
this manner takes into account any changes in blood flow due
to change in blood pressure and also better reflects absolute
changes in skin blood flow.
Following 30 minutes of rest, the hyperhemia was studied in
the following sequence: post-occlusive hyperhemia with a 20
minute recovery period; sublingual nitroglycerin challenge with
a 30 minute recovery period; and thermal hyperhemia. The
recovery periods, determined in pilot experiments, were such
that the cutaneous conductance returned to baseline values
within these periods.
Post-occlusive hyperhemia
After 10 minutes of rest, to allow for the measurement of base-
line cutaneous conductance, digital blood flow was occluded
for 5 minutes by inflating a cuff placed on the left arm to 50 mm
Hg above the systolic blood pressure. The cuff was then
released and the flow responses were recorded. The ampli-
tude of the response was determined by the peak hyperhemic
conductance, expressed as an absolute value (mV/mm Hg).
The kinetics of the response were determined by the time to
peak hyperhemia and duration of hyperhemia, expressed in
seconds.
Endothelium-independent response
Endothelium-independent vasodilation was tested 20 minutes
later, following blood pressure and heart rate measurements.
A single high dose of sublingual nitroglycerin (0.4 mg) was
given. Digital skin blood flow was continuously recorded. The
maximal effect was measured as the mean signal over a 1
minute period 4 minutes after nitroglycerin administration, sim-
ilar to what is used for vasodilation of the brachial artery [27].
The amplitude of the response was determined by the 4
minute peak conductance, expressed as mV/mm Hg.
Thermal response
We measured microvascular response to local heating 30
minutes later. The PR457 laser probe was heated to 42°C for
30 minutes and then to 44°C for 5 minutes. Laser Doppler
flow measured over the first 30 minutes is characterized in
healthy controls by an initial peak within the first 10 minutes
followed by a nadir and a final rise to a second peak that con-
tinues as a sustained plateau. Maximal skin blood flow is
achieved by heating to 44°C. The amplitude of the response
was determined by the 10 minute thermal peak, 10–30 minute
thermal peak, and 44°C thermal peak conductances,
expressed as absolute values (mV/mm Hg). The maximal
effects were measured as the mean signal over a 1 minute
period for the 10 minute thermal peak, and as the mean signals
over a 3 minute period for the 30 minute and 44°C thermal
peaks. In subjects without a clear-cut initial peak, the maximal
value of the first 10 minutes was measured as the mean signal
over a 1 minute period, corresponding to the highest mean
within the 10 minute window. The kinetics of the response
were determined by the time to first thermal peak, and the time
to second peak when available. The time to first peak was
determined from the onset of the probe heating to the first
peak, or to the maximal value when no clear plateau was
observed.
Reproducibility of laser Doppler measurements
Reproducibility was tested on 20 healthy subjects for the ther-
mal hyperhemic response, and on 10 healthy subjects for the
post-occlusive hyperhemic response. Post-occlusive hyper-
hemia and thermal hyperhemia were performed as detailed
above. Each examination was repeated 1 day after the end of
the first series on the same subject. For thermal hyperhemia,
the median absolute difference for the time to first thermal
peak was 13 s (10th-90th percentile: 4–60) for a median of the
means of 152 s (105–233). The median absolute difference
for the 10 minute thermal peak was 4.5 mV/mm Hg (0.3–46)
for a median of the means of 59 (20–81). For the post-occlu-
sive response, the median absolute difference for the time to
peak hyperhemia was 20 s (5–40) for a median of the means
of 44 s (23–74). The median absolute difference for the peak
hyperhemic conductance was 2 mV/mm Hg (0.5–9) for a
median of the means of 46 (26–59). The coefficient of corre-
lation for the time to first thermal peak and the 10 minute ther-
mal peak was 0.89 and 0.65, respectively. The coefficient of
correlation for the time to peak hyperhemia and peak hyper-
hemic conductance was 0.56 and 0.94, respectively. As cor-
relation coefficients are poor indicators of reproducibility,
Bland and Altman plots were constructed to measure the
agreement between both measures. For the four measures,
more than 95% of the differences were less than two standard
deviations, and neither proportional error nor systematic errors
were detected.Available online http://arthritis-research.com/content/7/5/R1103
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Data analysis
The mean time to first thermal peak was 154 s (standard devi-
ation 56) in the 20 healthy controls involved in the repeatability
study. Sample size calculations were based on the main objec-
tive, that is, to detect a difference in the time to first thermal
peak of at least 60 s between groups, with α  = 0.05 and
power (1-β ) = 0.9.
Quantitative data were analyzed with the following nonpara-
metric statistical methods: Kruskal-Wallis analysis of variance;
Mann-Whitney test for between groups comparisons; Wil-
coxon test for paired analysis; and Spearman rank correlation
test for the relationship between quantitative variables. Pro-
portions were compared by using Chi2 tests or Ficher's exact
test when appropriate. P-values less than 0.05, corrected by
Bonferroni's method for multiple comparison, were considered
significant. All quantitative data are expressed as the median,
10th and 90th percentiles. Qualitative data are expressed as
number and percentage.
Results
Clinical and biological characteristics
The demographic, clinical and biological characteristics of the
patients enrolled in the SSc study are listed in Table 1. Among
patients with SSc, one patient was treated with methotrexate,
one with cyclophosphamide and one with a synthetic antima-
larial drug. One patient in the RP group and eight in the SSc
group were on calcium channel blockers at the time of inclu-
sion and one of each group was on buflomedil. Both calcium
channel blockers and buflomedil were stopped 7 days before
enrollment in the study. Arterial pulmonary hypertension was
suspected in one SSc patient at the time of inclusion and con-
firmed by right heart catheterization.
In the second study, 10 patients with RA and 10 patients with
primary RP were enrolled. Their clinical and biological charac-
teristics are listed in Table 2. Among the patients with RA, all
were receiving infliximab, 50% oral corticosteroids, 40%
methotrexate and 30% non-steroidal anti-inflammatory drugs.
Comparison of thermal hyperhemia in systemic 
sclerosis, primary Raynaud's phenomenon and healthy 
controls
Thermal hyperhemia was dramatically altered in terms of kinet-
ics in patients with SSc (Table 3, Fig. 1). While 19 healthy vol-
unteers and 18 patients with primary RP exhibited the classic
response, including an initial peak within the first 10 minutes
followed by a nadir and a second peak, this occurred only in
four of the SSc patients (p < 0.0001). Similarly, a first peak
occurred within 10 minutes in all healthy volunteers and all
patients with primary RP, whereas an initial peak within 10
minutes was present in only 11 SSc patients (p < 0.0001).
The absence of the first peak had a sensitivity of 80% and a
specificity of 90% for differentiating SSc from primary RP, with
an accurary of 85%, a positive likehood ratio of 8 and a nega-
tive likehood ratio of 0.22. Thermal hyperhemia was also
altered in terms of amplitude (Table 3, Fig. 2).
The response to sublingual nitroglycerin did not significantly
differ between groups (Table 3). The amplitude and kinetics of
cutaneous vascular conductance response to occlusive
hyperhemia was altered in patients with SSc (Table 3).
Secondary objectives
The time to first thermal peak was correlated to the 10 minute
thermal peak amplitude (r = 0.38; p = 0.003). It was also cor-
related to the time to the post-occlusive peak hyperhemia (r =
0.29; p = 0.03). When introduced in a linear regression anal-
ysis model, both the 10 minute thermal peak amplitude and the
time to post-occlusive peak hyperhemia remained significant.
No correlation was found, however, between the time to first
thermal peak and the post-occlusive peak hyperhemic
conductance.
In the SSc group, the time to the first thermal peak was corre-
lated to the Rodnan's modified skin score (r = 0.6; p = 0.005).
The kinetics of both the thermal challenge and post-occlusive
hyperhemia were altered in patients with dcSSc in comparison
with lcSSc: the time to first thermal peak was 255 s (162–
Table 2
Demographic, clinical and biological characteristics of patients enrolled in the second study
Primary RP (n = 10) RA (n = 10)
Age (years) 55 (42–64) 53 (39–68)
Female 7 (70%) 7 (70%)
Body mass index (kg/m2) 22 (19–23) 25 (20–30)
Raynaud's phenomenon 10 (100%) 10 (100%)
Median disease duration (years) NA 9 (4–36)
Rheumatoid factor 0 9 (90%)
Disease Activity Score 28 NA 2.4 (2.3–4.9)
Quantitative data are medians, with 10th and 90th percentiles in parentheses. Qualitative data are expressed as numbers. NA, not applicable.Arthritis Research & Therapy    Vol 7 No 5    Boignard et al.
R1108
986) and 1395 s (412–1780) in patients with lcSSc and
dcSSc, respectively (p = 0.003), while the time to post-occlu-
sive peak hyperhemia was 78 s (13–250) and 159 s (123–
335), respectively (p = 0.05). In contrast, the amplitudes in
both tests were similar in patients with lcSSc and dcSSc.
Post hoc analysis
To test whether the lower conductance in response to heat in
the SSc group was just a consequence of lower microvascular
density, we normalized the thermal hyperhemia to the endothe-
lium-independent nitroglycerin response. The ratio of the 44°C
thermal peak minus baseline to the nitroglycerin peak minus
baseline was 14 (3–131), 19 (3–225) and 1.8 (0–20) in
healthy subjects, the RP group, and the SSc group, respec-
tively (p < 0.05).
We tested as a post hoc analysis whether the maximal con-
ductance between the whole thermal challenge (0 to 30 min-
utes) would differ between groups. The maximal conductance
was 43.4 (28–63), 42.6 (31–81) and 27.1 (17.6–52.3) mV/
mm Hg in the healthy volunteers, primary RP group and the
SSc group, respectively (p = 0.001).
Receiver-operating characteristic curve analyses
Receiver-operating characteristic curves for the diagnosis of
SSc in subjects with RP were plotted for the primary RP and
SSc patients. The area under the curve for the time to first ther-
mal peak was 0.87 (95% confidence interval 0.71–0.95), and
for the 10 minute thermal peak was 0.79 (95% confidence
interval 0.61–0.89). The area under the curve for the time to
peak hyperhemia was 0.75 (95% confidence interval 0.58–
0.87) and for the peak hyperhemic conductance was 0.47
(95% confidence interval 0.31–0.64). A time to first thermal
peak value higher than 180 s had a sensitivity of 90% and a
specificity of 70% for differentiating SSc from primary RP, with
an accurary of 80%, a positive likehood ratio of 3 and a nega-
tive likehood ratio of 0.14.
Specificity of the thermal response
To test whether other connective tissue disorders may share
the same pattern of altered response, we conducted a second
study in which thermal hyperhemia was performed in 10
patients with RA and 10 patients with primary RP. The thermal
hyperhemia was altered in terms of amplitude in patients with
RA (Fig. 2). Conversely, the thermal hyperhemia was not
altered in terms of kinetics in patients with RA. The time to
thermal peak was 222 s (116–1684) in RA versus 200 s
(134–266) in primary RP (not significantly different). Whereas
Figure 1
Thermal hypermemia in Raynaud's phenomenon (RP), limited and diffuse cutaneous systemic sclerosis (lcSSc and dcSSc) Thermal hypermemia in Raynaud's phenomenon (RP), limited and diffuse cutaneous systemic sclerosis (lcSSc and dcSSc). The patient with primary 
Raynaud's phenomenon has a normal response, including a first peak within the first 10 minutes and a nadir followed by a second plateau. This 
response is altered in the lcSSc patient, in which neither the initial cutaneous vascular conductance peak nor nadir is observed. The dcSSc patient 
shows a destructured response, including a delayed maximal response.Available online http://arthritis-research.com/content/7/5/R1103
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all patients with primary RP exhibited the classic response,
including an initial peak within the first 10 minutes followed by
a nadir and a second peak, this occurred in only 7 of the 10
RA patients (p = 0.06).
Discussion
Our study shows that hyperhemia to local heating is dramati-
cally altered in terms of kinetics and amplitude in patients with
SSc in comparison with patients with primary RP, the latter of
which behave similarly to healthy controls. Furthermore, while
the kinetics of the thermal response distinguish patients with
SSc from among those presenting with a RP, the altered pat-
tern of response is shared with other connective tissue dis-
eases such as RA.
Scleroderma spectrum disorders are heterogeneous diseases
with a large variation of clinical manifestations in individual
patients. At one end of the spectrum is undifferentiated con-
Figure 2
Amplitude of the thermal hyperhemia in systemic sclerosis (SSc) and rheumatoid arthritis Amplitude of the thermal hyperhemia in systemic sclerosis (SSc) and rheumatoid arthritis. (a) Patients with systemic sclerosis (SSc), primary Ray-
naud's phenomenon (RP) and healthy controls. (b) Patients with rheumatoid arthritis (RA) and primary RP. Data are expressed as box plots in which 
50% of values lie within the box. The horizontal line depicts the median value and the whiskers indicate the 10th and the 90th percentiles of all values.Arthritis Research & Therapy    Vol 7 No 5    Boignard et al.
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nective tissue disease, which includes the presence of RP and
a typical capillaroscopy scleroderma pattern or positivity for
Scl-70 or anticentromere antibodies; at the other end of the
spectrum is SSc. In this study, we chose to include patients
fulfilling the American College of Rheumatology criteria with
no evidence of overlap syndrome, in order to study definite
SSc cases rather than overlap or undifferentiated connective
tissue disease. Although laser Doppler has been widely used
to assess microvascular function in SSc, its utility in a clinical
setting has remained poor to date. Most groups have used
cold challenges, for which no specific pattern of response has
been observed. For example, in a previous study using laser
Doppler perfusion, we showed that although patients with
SSc had a lower cutaneous blood flow at baseline, the varia-
tion of response was similar to subjects with primary RP and
healthy controls when exposed to whole body cooling [13].
Conversely, post-occlusive and thermal hyperhemia provide
information on the endothelial and microvascular function.
Until recently, the mechanisms mediating post-occlusive
hyperemia were still unknown. Two recent studies, however,
specifically tested the contribution of two major endothelium-
derived mediators, specifically NO and prostacyclin. Cycloox-
ygenase inhibition decreases the post-occlusive hyperemic
response [16], whereas NO synthase inhibition does not
affect it [16,18]. Furthermore, NO concentration does not
increase during post-occlusive hyperhemia [28]. These stud-
ies clearly show that the endothelial part of the response is
prostacyclin but not NO dependent. Conversely, the sustained
plateau phase in response to local hyperthermia is NO-
dependent [19,20]. Therefore, these tests clearly do not
explore the same pathways of endothelial function. Although
we show that the kinetics of the response in both tests are cor-
related, this correlation is weak.
Although post-occlusive hyperhemia is altered in patients with
SSc [12,14], the response is also weakly altered in subjects
with primary RP [14], something that we also observed in the
present study. In contrast, we show that thermal hyperhemia is
normal in subjects with primary RP. As both functional tests
explore different mediators of endothelial function, this sug-
gests that thermal hyperhemia could be more specific for SSc
or other connective tissue disease vascular dysfunction,
whereas post-occlusive hyperemia could be more sensitive to
the RP itself. Our descriptive data, however, do not elucidate
Table 3
Induced hyperhemia in patients with systemic sclerosis or primary Raynaud's phenomenon and healthy controls
Healthy controls (n = 20) Primary RP (n = 20) SSc (n = 20) P-value
Amplitude of the thermal response (median cutaneous 
vascular conductance (mV/mm Hg), 10th-90th percentile)
Baseline 7.2 (1.1–38) 6.4 (1.4–26.3) 5.2 (1.2–25.9) NS
10 min thermal peak 43.4 (23.2–63) 42.6 (31–80.7) 27 (14.7–51.4)a 0.01
10–30 min thermal peak 35.5 (12.2–55) 37.2 (24.3–70.6) 24.7 (13.5–51) 0.09
44°C thermal peak 43.1 (21.3–62.1) 42.6 (31.6–74.3) 25.4 (15–52.4)a 0.01
Kinetics of the thermal response (median time, seconds)
Time to first thermal peak 190 (125–230) 160 (91–311) 391 (171–1483)a 0.0001
Time to second peak 1458 (867–1949) 1394 (967–1991) - NS
Amplitude of the response to sublingual nitroglycerin (median 
vascular conductance (mV/mm Hg), 10th-90th percentile)
Baseline 14.1 (1.1–54.2) 4.6 (0.8–32) 11.5 (1.4–38) NS
4 min peak 16.5 (1.6–55) 9.1 (1.2–34.5) 16.8 (3.6–37.7) NS
Amplitude of the post-occlusive response (median cutaneous 
vascular conductance (mV/mm Hg), 10th-90th percentile)
Baseline conductance 13 (1.3–49) 4.8 (1.1–32) 7.7 (1.4–30) NS
Peak hyperhemic conductance 36.8 (11–65) 28.5 (9.3–49) 25.1 (9.5–50.2)b 0.05
Kinetics of the post-occlusive response (median time 
(seconds) 10th-90th percentile)
Time to peak hyperhemia 34.3 (17.4–76.5) 44.4 (19.8–104) 108.5 (15–287)a 0.003
Duration of hyperhemia 165 (75–277) 150 (97–345) 225 (82–345) NS
Data are medians, with 10th and 90th percentiles in parentheses. Cutaneous blood flow is expressed as cutaneous conductance (mV/mm Hg). Local 
heating at 42°C was applied for 30 minutes, followed by 5 minutes heating at 44°C. The cutaneous blood conductance was measured on the left 
middle fingerpad. aP < 0.05 following Bonferroni's correction versus healthy controls and versus primary Raynaud's phenomenon (RP), Mann-
Whitney test. bP < 0.05 following Bonferroni's correction versus healthy controls. SSc, systemic sclerosis.Available online http://arthritis-research.com/content/7/5/R1103
R1111
the specific mechanisms of the altered thermal hyperhemic
response. Indeed, most of the patients with SSc do not exhibit
the classic initial peak followed by a nadir. Whereas the
impaired thermal hyperhemia in terms of amplitude could be
related to a decreased ability to release NO, the altered kinet-
ics of response could be related either to a local impaired axon
reflex mediated vasodilation or to an inability to increase cuta-
neous blood flow due to macrovascular disease, including
ulnar and digital artery narrowing. Further studies are also
required to determine whether this impairment is correlated to
the morphological changes or whether it precedes them.
A concern about laser Doppler flowmetry is reproducibility.
We found the reproducibility to be correct for the first thermal
peak, the 10 minute thermal peak and the post-occlusive peak
hyperhemic conductance but not for the post-occlusive time
to peak hyperhemia. A significant limitation when using laser
Doppler flowmetry is the normalization to baseline. When
using normalization, the ratio is highly dependent on the base-
line values, which are very variable, leading to a poor reproduc-
ibility. In previous experiments using microdialysis, we
normalized to a maximum dilation observed during sodium
nitroprusside infusion [18], but whereas this is the ideal way to
normalize the response, this can not be done in a clinical set-
ting given the invasive approach. In this study we instead used
an indirect approach (a sublingual spray of nitroglycerin) that
induces an endothelium independent vasodilation. The effect
of nitroglycerin was similar in the three groups studied and
was also similar to what was observed after brachial artery
infusion of sodium nitroprusside [3]. As the ratio of thermal
hyperhemia over the nitroglycerin hyperhemia was much lower
in the SSc group compared to the other groups, we may con-
clude that the lower maximal amplitude of thermal hyperhemia
is not only related to the decreased capillary density, but to a
decreased response to the thermal challenge.
To test whether an altered response to thermal hyperhemia
was specific for SSc, we carried out a second study in which
patients with RA suffering from Raynaud's phenomenon were
enrolled. A potential pitfall in this study was the inclusion of
patients receiving infliximab, which may itself improve
endothelial function [29]. Furthermore, patients had a mini-
mally active disease as suggested by their median disease
activity score of 28, and the results may differ in patients with
active RA. We clearly showed, however, that thermal hyper-
hemia is altered in RA as well as in SSc in terms of amplitude.
As a consequence, an altered vascular response to local heat-
ing seems to be a hallmark of secondary RP, and is not dis-
ease specific. Indeed, there is strong evidence that endothelial
dysfunction is present in patients with RA with both high and
low disease activity scores [29,30]. While these two studies
were performed using brachial artery flow mediated dilation,
that is, analysis of a large conductance artery, we show that
the NO-dependent second peak to local heating is impaired in
RA, suggesting an abnormality of the microvascular endothe-
lium. Conversely to the altered response in terms of amplitude,
we were not able to demonstrate a difference in terms of kinet-
ics in RA in comparison with primary RP. As the number of
patients studied was small, further studies are required to
determine whether this is due to a lack of power to detect a
weak difference, or to a real similarity in the kinetic response.
We still need to determine in future studies whether the abnor-
mal response to local heating in SSc and RA differs with
respect to the pathogenic mechanisms.
Noninvasive determination of microvascular dysfunction as an
early event in the disease process remains a great challenge.
Indeed, most patients with SSc initially only present an RP,
which preceeds the cutaneous and/or pulmonary fibrosis. To
date, nailfold capillaroscopy and detection of autoantibodies
are used to determine which patients are susceptible for the
development of SSc. At this time, there is still place for a non-
invasive functional test. Our data suggest that the response to
local heating could help to distinguish patients with secondary
RP among those presenting with RP. This has to be confirmed
in a prospective follow-up cohort study, however, to determine
whether the thermal test could prospectively discriminate
those patients presenting with RP who will develop clinical
signs of connective tissue diseases. We are also planning a
study to include patients with RP presenting with nailfold cap-
illaroscopy abnormalities and/or autoantibodies that do not
meet the criteria for SSc diagnosis to determine whether the
alteration of the thermal response is an early event in the dis-
ease course.
Conclusion
An effective test for endothelial and microvascular function
would be an important advance in the diagnosis and monitor-
ing response to treatment in scleroderma spectrum disorders.
Thermal hyperhemia is dramatically altered in patients with
secondary RP in comparison with subjects with primary RP.
Further studies are required to determine the mechanisms of
this altered response, and whether it may provide additional
information in a clinical setting.
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